A5033485637- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Renal and related cancers
- RNA and protein synthesis mechanisms
- Genomics and Rare Diseases
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- CRISPR and Genetic Engineering
- Ovarian cancer diagnosis and treatment
- Cutaneous Melanoma Detection and Management
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immunotherapy and Immune Responses
- Gallbladder and Bile Duct Disorders
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Uterine Myomas and Treatments
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- BRCA gene mutations in cancer
Queen Elizabeth Hospital
2023-2024
The University of Adelaide
2024
Flinders University
2022
Royal Marsden NHS Foundation Trust
2020-2021
Flinders Medical Centre
2021
Institute of Cancer Research
2021
Royal Adelaide Hospital
2020
Introduction The outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing.
Despite the increasing incidence of metastatic melanoma in older population, there are relatively limited data for those than 75 years age. Elderly patients often under-represented clinical trials. In addition, elderly trials have a lower Eastern Cooperative Oncology Group score and fewer comorbidities may thus not truly reflect realities day-to-day practice. We present case 95-year-old woman who had extensive unresectable subcutaneous dermal deposits her right leg, which caused oedema...